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Chapter 1: Introduction 
 Cancer, the age-old immortal illness, arises from uncontrolled division of a 
set of diseased cells which can be identified with a limitless replicative potential as 
well as the capacity of out-of-bound migration, invasion and metastasis. The loss of 
cellular regulation leading to cancer may often arise from mutations in two broad 
classes of genes, namely, oncogenes and tumor suppressor genes. Though cancer is 
often described as ‘The wound that never heals’, there have been intense efforts 
worldwide to bring a remedy including hormonal therapy, targeted chemotherapy, 
cancer immunotherapy, gene therapy, anti-angiogenic therapy etc. 
Chemotherapy usually refers to use of drugs (chemotherapeutics) that kill 
rapidly dividing cancer cells. While chemo drugs kill cancer cells, they also harm 
cells that divide rapidly under normal conditions. Such side effects are partly 
overcome by targeted therapy which is a special type of chemotherapy that takes 
advantage of small differences between normal cells and cancer cells (“molecular 
targets”), thereby selectively delivering drugs to cancer cells via suitable drug 
delivery systems.  
Drug delivery systems refer to approaches, formulations, and systems for 
transporting a pharmaceutical compound in the body to safely achieve its desired 
therapeutic effect. These include liposomes, microspheres, gels, polymers, 
nanoparticles, micelles, cyclodextrins etc. Liposomes, consisting of spherical lipid 
bilayers and enclosing a watery interior, have long been viewed as bio-compatible 
drug/gene delivery reagents owing to their structural similarity to cell membranes. In 
the field of targeted chemotherapy, specific targeting of liposomally encapsulated 
chemotherapeutics to tumor cells are often accomplished using liposomes made from 
lipids covalently conjugated with tumor targeting ligands. Past decade has also 
witnessed wide use of Gold nanoparticles (GNPs) in the field of nanomedicine with 
diverse biomedical applications such as drug delivery vehicles or theranostic agents.
 
Due to their small size, good biocompatibility, tailor-able surface chemistry, 
characteristic surface plasmon absorption, and ease of synthesis, gold nanoparticles 





Despite significant advances, resistance to chemotherapy and molecularly 
targeted therapies is a major challenge in current cancer research. The resistance to 
‘classical’ cytotoxic chemotherapeutics and to therapies that are designed to be 
selective for specific molecular targets may be intrinsic or acquired. The most 
common reason for acquisition of resistance to a broad range of anticancer drugs is 
expression of one or more energy-dependent transporters that detect and eject 
anticancer drugs from cells, but other mechanisms of resistance including 
insensitivity to drug-induced apoptosis and induction of drug-detoxifying 
mechanisms also play an important role in acquired anticancer drug resistance. 
Multidrug based combination therapy sometimes helps to circumvent such resistance 
of cancer cells to chemotherapeutics. Rational drug combinations are often proposed 
on the basis of in vitro and in vivo synergy between agents; either hitting the same 
pathway at multiple points or targeting completely independent pathways. Thus, 
strategies to circumvent cancer drug resistance by targeting alternative pathways may 
improve cancer chemo therapy leading to efficient tumor management. 
Here, in my thesis, I report on the exploitation of two targets: Glucocorticoid 
receptor and N-end rule pathway as a strategy to induce drug sensitization in cancer 
cells and inhibit tumor regression (melanoma & colon).  
Chapter 2 
 The differentiation of epithelial cells to motile mesenchymal phenotype, a 
process known as epithelial-mesenchymal transition (EMT) is involved in drug 
resistance, cancer progression and metastasis. Therefore, inhibiting EMT could be an 
attractive therapeutic modality to overcome drug resistance and metastasis in cancer 
cells. Recent studies demonstrate that glucocorticoids (GCs), a class of steroid 
hormones can block EMT of mink lung epithelial cells, estrogen receptor (ER) 
negative breast cancer cells and human peritoneal mesothelial cells. However, 
elucidation of role of glucocorticoids in inducing EMT has just started and 
glucocorticoid receptor’s (GR) functional importance in this regard is not clear yet. 
Chapter 2 of my thesis delineates the development of a new glucocorticoid receptor 
(GR)-targeted gold nanoparticle formulation, that can stably carry anticancer drug 
Withaferin A (WFA) in its hydrophobic core. To achieve GR target-ability, we 





bond. The primary –OH group of dexamethasone was converted into thiol 
functionality (DSH) to ensure facile binding with gold nanoparticle surface. The 
presently synthesized gold nanoparticle formulation (GNP-DSH-WFA) showed GR-
dependent cancer cell selective cytotoxicity, inhibited growth of aggressive mouse 
melanoma tumor while reversing EMT in tumor-associated cells and reduced mice 
mortality. Same treatment also led to near-complete down-regulation of ABCG2 
drug transporter in tumor cells thereby attributing it to its drug sensitization ability. 
The present report thus demonstrates the design of a new metallic nano-formulation 
that reduces aggressive tumor growth through GR-mediated reversal of EMT and 
induction of drug sensitivity. 
 
 
Figure 1. Glucocorticoid receptor targeted gold nanoconjugates inhibit tumor growth in mice via 
EMT reversal. Schematic representation of Glucocorticoid receptor targeted gold-withaferin 
nanoconjugate and its application in inhibiting growth of melanoma tumor in mice while reversing 
EMT in tumor cells. 
Chapter 3A 
 Biotin (vitamin B7, vitamin H) is an essential micronutrient for normal 
cellular functions and is required in excess by various cancer cells to sustain their 
rapid proliferation. Biotin receptor is often found to be over expressed in a number of 





molecular marker for targeted drug delivery. This chapter reports on the synthesis of 
a biotin based amphiphilic lipid, BIO-C18, which along with appropriate co-lipids in 
particular mole ratios form stable liposome. Cellular uptake study demonstrates that 
Rhodamine PE labelled liposomes of BIO-C18 lipid efficiently internalize in CT26, 
A549 and Hela cells via biotin receptor. This liposome can also preferentially deliver 
a hydrophobic fluorescent molecule in mice bearing colon tumor (biotin receptor 
over-expressed) under in vivo settings. 
 
Figure 2. Cellular uptake of liposomes of biotinylated amphiphile are biotin receptor mediated. 
Structure of biotin derived amphiphile, BIO-C18 (A) and schematic representation of biotin receptor 
targeted liposome (B) of BIO-C18. Flow cytometric uptake analysis (C) of Rh-PE liposome of BIO-
C18 (red) which decreased considerably (blue) when cells were pre-saturated with biotin when 
compared to untreated (black). 
 Chapter 3B  
N-end rule pathway is an ubiquitin dependent protein degradation pathway 
that relates the in vivo half-life of a protein to the identity of its N-terminal residue. 
Recent study has shown that N-end rule pathway counteracts cell death by degrading 
many anti-survival protein fragments like BCLxL, BRCA1, RIPK1 etc. Inhibition of 
the N-end rule pathway can lead to metabolic stabilization of pro-apoptotic protein 
fragments like RIPK1, thereby sensitizing cells to programmed cell death. Receptor 
interacting serine-threonine protein kinase-1 (RIPK1) is one of the upstream 
regulators of programmed necrosis known as necroptosis. Necroptosis is particularly 
gaining attention of cancer biologists as it provides an alternate therapeutic modality 
to kill cancer cells, which often evolve multiple strategies to circumvent growth 





cells, herein, we report that co-administration of synthetic hetero-bivalent N-end rule 
inhibitor RFC11 & anticancer drug shikonin solubilized in a stable biotin receptor-
targeted liposome (described in Chapter 3A) exhibited significant synergistic anti-
tumor effect in both subcutaneous and orthotopic mouse colon tumor model through 
induction of necroptosis. Besides developing a newly targeted formulation for 
necroptosis induction, this report is the first in vivo evidence demonstrating that 




Figure 3. RFC11 & shikonin co-solubilised within the liposomes of BIO-C18 synergistically inhibit 
colon tumor growth via induction of necroptosis. Structure of RFC11 (A). Viability assay showing 
RFC11 could synergise anticancer effect of shikonin in colon cancer cell (B). Transmission electron 
micrograph of CT26 cell showing signs of necroptosis (C). Representative tumor size (D) in mice 
bearing orthotopic and subcutaneous colon tumor treated with glucose (I), biotinylated liposomes 
containing RFC11(II), shikonin (III), both RFC11 & shikonin (IV). 
Conclusion 
My thesis work thus focuses on the development of two different nano-
assemblies, one liposomal and other gold nanoparticle based, both when loaded with 
suitable adjuvant could sensitize cancer cells to chemotherapeutics leading to 
efficient tumor growth inhibition in melanoma and colon carcinoma. The present 
thesis work also demonstrates that inhibition of N-end rule pathway can act as a 
platform to enhance therapeutic efficacy of conventional chemotherapeutics, thus 
opening new prospects in the field of cancer chemotherapy. 
